A Phase 3 interventional study of Standard of care and Apremilast in COVID-19, sponsored by Amgen. Completed at 59 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 303rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 174 in phase 3, and was the 749th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 515 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
This adaptive, randomized, placebo-controlled platform study is designed to rapidly assess multiple candidate agents as treatments for COVID-19 in hospitalized patients. Candidate agents will be evaluated frequently (through ongoing monitoring) for futility and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
For inclusion, participants will need to be hospitalized with a clinical status of Grade 2 to Grade 5, as defined by the following Clinical Severity Status 8-Point Ordinal Scale:
Participants will be randomized equally to either the candidate agent plus standard of care (SoC) or placebo plus SoC in a double-blind fashion. Participants who are randomized to placebo plus SoC will subsequently be randomized equally to a matching placebo corresponding to an available agent whose sub-protocol the patient qualified for (ie, a 2-stage randomization). Each participant in the placebo plus SoC group will only receive one type of placebo. Randomization will be stratified by baseline clinical severity of 2 on the 8-point ordinal scale (yes/no) and remdesivir use at baseline (yes/no).
The study will evaluate each candidate agent separately as an add-on to the SoC to assess safety and efficacy. The comparator group for a candidate agent will include participants randomized to the placebo arm of any sub-protocol according to the following conditions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male participants:
Female participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
Drug: Standard of care · Drug: Apremilast
Participants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.
Drug: Standard of care · Drug: Apremilast placebo
Participants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
Drug: Standard of care · Drug: Lanadelumab
Participants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.
Drug: Standard of care · Drug: Lanadelumab placebo
Participants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
Drug: Standard of care · Drug: Zilucoplan
Participants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.
Drug: Standard of care · Drug: Zilucoplan placebo
Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Apremilast administered orally as a tablet.
Also known as: Otezla
Matching apremilast placebo administered orally as a tablet.
Lanadelumab administered as an intravenous (IV) infusion.
Also known as: TAKHZYRO™, TAK-743
Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.
Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.
Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.
Time frame: Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29
Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.
Time frame: Day 29
Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29
Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Baseline (Day 1) and Day 29
Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29
All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.
Time frame: Day 1 to Day 29
Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29
The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.
Time frame: Day 8, Day 15, and Day 29
Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29
The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 2 to Day 29
Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29
Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).
Time frame: Day 1 to Day 29
Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29
Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.
Time frame: Day 1 to Day 29
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29
Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 8, Day 15, and Day 29
Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery
Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 60
Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE): * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.
Time frame: From first dose of study drug to end of study (Day 60)
Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29
Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.
Time frame: Day 29
Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29
Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Baseline (Day 1) and Day 29
Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29
All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.
Time frame: Day 1 to Day 29
Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29
The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.
Time frame: Day 8, Day 15, and Day 29
Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29
The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 2 to Day 29
Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29
Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).
Time frame: Day 1 to Day 29
Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29
Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.
Time frame: Day 1 to Day 29
Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29
Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 8, Day 15, and Day 29
Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery
Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 60
Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.
Time frame: From first dose of study drug to end of study (Day 60)
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29
Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.
Time frame: Day 29
Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29
Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Baseline (Day 1) and Day 29
Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29
All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.
Time frame: Day 1 to Day 29
Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29
The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.
Time frame: Day 8, Day 15, and Day 29
Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29
The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 2 to Day 29
Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29
Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).
Time frame: Day 1 to Day 29
Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29
Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.
Time frame: Day 1 to Day 29
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29
Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 8, Day 15, and Day 29
Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery
Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
Time frame: Day 60
Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events
An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.
Time frame: From first dose of study drug to end of study (Day 60)
This adaptive platform study consisted of 3 sub-protocols, each designed to assess a candidate agent as treatment for coronavirus disease 2019 (COVID-19) in hospitalized adult patients who had severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. The control group for a candidate agent includes participants randomized to any matching placebo for a candidate agent if certain criteria were met (shared placebo).
| Milestone | Lanadelumab + Standard of Care | Lanadelumab Placebo + Standard of Care | Apremilast + Standard of Care | Apremilast Placebo + Standard of Care | Zilucoplan + Standard of Care | Zilucoplan Placebo + Standard of Care |
|---|---|---|---|---|---|---|
| Started | 28 | 1 | 194 | 184 | 100 | 8 |
| Received study drug | 27 | 1 | 189 | 182 | 95 | 7 |
| Full analysis set | 28 | 34 | 194 | 190 | 100 | 75 |
| Completed | 15 | 0 | 139 | 138 | 70 | 4 |
| Not completed | 13 | 1 | 55 | 46 | 30 | 4 |
| Withdrew: Death | 7 | 1 | 37 | 34 | 19 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 | 11 | 11 | 6 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 0 | 3 | 0 |
| Withdrew: Other | 3 | 0 | 1 | 1 | 2 | 1 |
Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.
| days | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | 10.0 (5.00 to NA) | 15.5 (8.00 to NA) |
Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.
| days | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | 14.0 (11.00 to 15.00) | 14.0 (11.00 to 15.00) |
Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29. The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.
| days | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | 14.0 (11.00 to 22.0) | 15.0 (11.00 to 22.00) |
Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.
| percentage of participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | 52.0 (31.31 to 72.20) | 56.7 (37.43 to 74.54) |
Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | 72.0 (50.61 to 87.93) | 63.3 (43.86 to 80.07) |
All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.
| percentage of participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | 32.0 (14.95 to 53.50) | 30.0 (14.73 to 49.40) |
The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.
| Participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Day 8 — 1 (Death or discharged to hospice care) | 3 | 3 |
| Day 8 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 4 | 6 |
| Day 8 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 3 | 4 |
| Day 8 — 4 (Hospitalized, requiring supplemental oxygen) | 2 | 6 |
| Day 8 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 1 | 0 |
| Day 8 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 1 | 1 |
| Day 8 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 2 | 3 |
| Day 8 — 8 (Not hospitalized, no limitations on activities) | 8 | 7 |
| Day 8 — Missing | 1 | 0 |
| Day 15 — 1 (Death or discharged to hospice care) | 3 | 7 |
| Day 15 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 3 | 4 |
| Day 15 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 1 | 0 |
| Day 15 — 4 (Hospitalized, requiring supplemental oxygen) | 0 | 2 |
| Day 15 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 0 | 0 |
| Day 15 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 1 |
| Day 15 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 5 | 3 |
| Day 15 — 8 (Not hospitalized, no limitations on activities) | 12 | 13 |
| Day 15 — Missing | 1 | 0 |
| Day 29 — 1 (Death or discharged to hospice care) | 7 | 9 |
| Day 29 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 0 | 2 |
| Day 29 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 0 | 0 |
| Day 29 — 4 (Hospitalized, requiring supplemental oxygen) | 0 | 0 |
| Day 29 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 0 | 0 |
| Day 29 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 0 |
| Day 29 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 5 | 6 |
| Day 29 — 8 (Not hospitalized, no limitations on activities) | 12 | 13 |
| Day 29 — Missing | 1 | 0 |
The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| Participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| 1 (Death or discharged to hospice care) | 8 | 9 |
| 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 0 | 4 |
| 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 6 | 5 |
| 4 (Hospitalized, requiring supplemental oxygen) | 8 | 11 |
| 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 1 | 0 |
| 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 0 |
| 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 0 | 0 |
| 8 (Not hospitalized, no limitations on activities) | 1 | 1 |
| Missing | 1 | 0 |
Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).
| Participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| 0 days | 13 | 10 |
| 1 day | 1 | 1 |
| 3 days | 0 | 1 |
| 5 days | 0 | 1 |
| 6 days | 0 | 2 |
| 8 days | 1 | 3 |
| 11 days | 2 | 0 |
| 13 days | 1 | 1 |
| 15 days | 0 | 1 |
| 21 days | 0 | 1 |
| 30 days (death or discharged to hospice care) | 7 | 9 |
Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.
| Participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| 0 days | 17 | 18 |
| 6 days | 0 | 1 |
| 16 days | 0 | 1 |
| 24 days | 0 | 1 |
| 30 days (death or discharged to hospice care) | 8 | 9 |
Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Day 8 | 44.0 (24.40 to 65.07) | 36.7 (19.93 to 56.14) |
| Day 15 | 56.0 (34.93 to 75.60) | 56.7 (37.43 to 75.54) |
| Day 29 | 60.0 (38.67 to 78.87) | 63.3 (43.86 to 80.07) |
Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control |
|---|---|---|
| Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery | 40.0 (21.13 to 61.33) | 56.7 (37.43 to 74.54) |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE): * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.
| Participants | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Lanadelumab Placebo + Standard of Care |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 17 | 22 | 1 |
| TEAE with a CTCAE grade ≥ 3 | 11 | 18 | 1 |
| Serious TEAE | 11 | 18 | 1 |
| TEAE leading to dose modification | 2 | 3 | 0 |
| TEAE leading to discontinuation of study drug | 1 | 5 | 0 |
Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.
| percentage of participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | 59.8 | 63.7 |
Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | 74.7 | 77.9 |
All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.
| percentage of participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | 17.5 | 17.4 |
The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.
| Participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Day 8 — 1 (Death or discharged to hospice care) | 11 | 8 |
| Day 8 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 22 | 20 |
| Day 8 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 25 | 26 |
| Day 8 — 4 (Hospitalized, requiring supplemental oxygen) | 26 | 26 |
| Day 8 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 31 | 40 |
| Day 8 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 1 |
| Day 8 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 36 | 33 |
| Day 8 — 8 (Not hospitalized, no limitations on activities) | 38 | 34 |
| Day 8 — Missing | 5 | 2 |
| Day 15 — 1 (Death or discharged to hospice care) | 22 | 24 |
| Day 15 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 16 | 13 |
| Day 15 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 9 | 9 |
| Day 15 — 4 (Hospitalized, requiring supplemental oxygen) | 9 | 8 |
| Day 15 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 10 | 5 |
| Day 15 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 2 |
| Day 15 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 46 | 48 |
| Day 15 — 8 (Not hospitalized, no limitations on activities) | 78 | 79 |
| Day 15 — Missing | 4 | 2 |
| Day 29 — 1 (Death or discharged to hospice care) | 34 | 31 |
| Day 29 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 6 | 6 |
| Day 29 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 0 | 3 |
| Day 29 — 4 (Hospitalized, requiring supplemental oxygen) | 6 | 1 |
| Day 29 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 0 | 1 |
| Day 29 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 2 |
| Day 29 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 34 | 40 |
| Day 29 — 8 (Not hospitalized, no limitations on activities) | 110 | 104 |
| Day 29 — Missing | 4 | 2 |
The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| Participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| 1 (Death or discharged to hospice care) | 34 | 31 |
| 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 13 | 10 |
| 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 37 | 43 |
| 4 (Hospitalized, requiring supplemental oxygen) | 75 | 62 |
| 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 21 | 35 |
| 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 0 |
| 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 5 | 2 |
| 8 (Not hospitalized, no limitations on activities) | 5 | 5 |
| Missing | 4 | 2 |
Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).
| Participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| 0 days | 124 | 122 |
| 1 day | 4 | 2 |
| 2 days | 2 | 1 |
| 3 days | 2 | 4 |
| 4 days | 0 | 1 |
| 5 days | 4 | 1 |
| 6 days | 2 | 3 |
| 7 days | 4 | 2 |
| 8 days | 2 | 4 |
| 9 days | 1 | 1 |
| 10 days | 1 | 1 |
| 11 days | 0 | 1 |
| 12 days | 1 | 1 |
| 13 days | 0 | 2 |
| 14 days | 2 | 0 |
| 15 days | 0 | 1 |
| 17 days | 0 | 2 |
| 18 days | 0 | 1 |
| 20 days | 0 | 1 |
| 21 days | 0 | 2 |
| 23 days | 0 | 2 |
| 25 days | 1 | 0 |
| 27 days | 1 | 1 |
| 28 days | 1 | 0 |
| 29 days | 8 | 2 |
| 30 days (death or discharged to hospice care) | 34 | 32 |
Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.
| Participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| 0 days | 147 | 147 |
| 6 days | 1 | 1 |
| 9 days | 1 | 0 |
| 10 days | 1 | 0 |
| 11 days | 1 | 1 |
| 12 days | 0 | 1 |
| 13 days | 2 | 0 |
| 16 days | 0 | 2 |
| 18 days | 0 | 1 |
| 19 days | 1 | 0 |
| 22 days | 1 | 0 |
| 23 days | 0 | 1 |
| 24 days | 0 | 1 |
| 25 days | 3 | 1 |
| 26 days | 1 | 1 |
| 29 days | 1 | 0 |
| 30 days (death or discharged to hospice care) | 34 | 33 |
Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Day 8 | 36.6 | 35.8 |
| Day 15 | 57.7 | 60.0 |
| Day 29 | 66.0 | 72.1 |
Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Apremilast + Standard of Care | Apremilast Placebo Control |
|---|---|---|
| Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery | 66.0 | 66.3 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.
| Participants | Apremilast + Standard of Care | Apremilast Placebo Control | Apremilast Placebo + Standard of Care |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 102 | 103 | 100 |
| TEAE with a CTCAE grade ≥ 3 | 48 | 57 | 54 |
| Serious TEAE | 51 | 57 | 55 |
| TEAE leading to dose modification | 16 | 6 | 6 |
| TEAE leading to discontinuation of study drug | 9 | 12 | 11 |
Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.
| percentage of participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | 54.0 (43.74 to 64.02) | 60.0 (48.04 to 71.15) |
Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29. The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | 66.0 (55.85 to 75.18) | 69.3 (57.62 to 79.47) |
All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.
| percentage of participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | 18.0 (11.03 to 26.95) | 24.0 (14.89 to 35.25) |
The clinical severity status 8-point ordinal scale scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.
| Participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Day 8 — 1 (Death or discharged to hospice care) | 5 | 5 |
| Day 8 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 24 | 14 |
| Day 8 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 12 | 8 |
| Day 8 — 4 (Hospitalized, requiring supplemental oxygen) | 16 | 14 |
| Day 8 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 5 | 10 |
| Day 8 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 1 |
| Day 8 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 22 | 9 |
| Day 8 — 8 (Not hospitalized, no limitations on activities) | 11 | 12 |
| Day 8 — Missing | 5 | 2 |
| Day 15 — 1 (Death or discharged to hospice care) | 8 | 14 |
| Day 15 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 16 | 7 |
| Day 15 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 3 | 3 |
| Day 15 — 4 (Hospitalized, requiring supplemental oxygen) | 10 | 6 |
| Day 15 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 2 | 2 |
| Day 15 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 1 |
| Day 15 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 25 | 14 |
| Day 15 — 8 (Not hospitalized, no limitations on activities) | 31 | 26 |
| Day 15 — Missing | 5 | 2 |
| Day 29 — 1 (Death or discharged to hospice care) | 14 | 18 |
| Day 29 — 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 10 | 2 |
| Day 29 — 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 1 | 1 |
| Day 29 — 4 (Hospitalized, requiring supplemental oxygen) | 5 | 1 |
| Day 29 — 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 1 | 0 |
| Day 29 — 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 2 |
| Day 29 — 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 20 | 14 |
| Day 29 — 8 (Not hospitalized, no limitations on activities) | 44 | 35 |
| Day 29 — Missing | 5 | 2 |
The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint. The clinical severity status 8-point ordinal scale scores scores are: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| Participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| 1 (Death or discharged to hospice care) | 14 | 18 |
| 2 (Hospitalized on invasive mechanical ventilation or ECMO) | 21 | 6 |
| 3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices) | 24 | 12 |
| 4 (Hospitalized, requiring supplemental oxygen) | 30 | 29 |
| 5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care) | 5 | 7 |
| 6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care) | 0 | 0 |
| 7 (Not hospitalized, limitation on activities and/or requiring home oxygen) | 1 | 0 |
| 8 (Not hospitalized, no limitations on activities) | 0 | 1 |
| Missing | 5 | 2 |
Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).
| Participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| 0 days | 56 | 34 |
| 1 day | 0 | 2 |
| 3 days | 2 | 2 |
| 4 days | 0 | 1 |
| 5 days | 1 | 1 |
| 6 days | 1 | 3 |
| 7 days | 4 | 0 |
| 8 days | 0 | 4 |
| 9 days | 3 | 1 |
| 10 days | 0 | 1 |
| 11 days | 1 | 0 |
| 13 days | 1 | 2 |
| 14 days | 1 | 0 |
| 15 days | 0 | 1 |
| 17 days | 1 | 1 |
| 18 days | 1 | 0 |
| 21 days | 0 | 2 |
| 22 days | 1 | 0 |
| 25 days | 1 | 0 |
| 26 days | 1 | 0 |
| 29 days | 8 | 2 |
| 30 days (death or discharged to hospice care) | 17 | 18 |
Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.
| Participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| 0 days | 67 | 52 |
| 6 days | 0 | 1 |
| 7 days | 4 | 0 |
| 9 days | 1 | 0 |
| 10 days | 1 | 0 |
| 12 days | 0 | 1 |
| 13 days | 1 | 0 |
| 16 days | 0 | 1 |
| 18 days | 1 | 0 |
| 22 days | 1 | 0 |
| 24 days | 1 | 1 |
| 25 days | 1 | 0 |
| 26 days | 1 | 1 |
| 27 days | 1 | 0 |
| 28 days | 1 | 0 |
| 29 days | 1 | 0 |
| 30 days (death or discharged to hospice care) | 18 | 18 |
Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Day 8 | 33.0 (23.92 to 43.12) | 30.7 (20.53 to 42.38) |
| Day 15 | 53.0 (42.76 to 63.06) | 53.3 (41.45 to 64.95) |
| Day 29 | 60.0 (49.72 to 69.67) | 66.7 (54.83 to 77.14) |
Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery. Clinical severity status 8-point ordinal scale: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on noninvasive ventilation or high flow oxygen devices 4. Hospitalized, requiring supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care 6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care 7. Not hospitalized, limitation on activities and/or requiring home oxygen 8. Not hospitalized, no limitations on activities
| percentage of participants | Zilucoplan + Standard of Care | Zilucoplan Placebo Control |
|---|---|---|
| Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery | 55.0 (44.73 to 64.97) | 64.0 (52.09 to 74.77) |
An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above. The Investigator assessed the intensity of each AE according to the CTCAE grades: * Grade 1 Mild; asymptomatic or mild symptoms; * Grade 2 Moderate; minimal, local or noninvasive intervention indicated; * Grade 3 Severe or medically significant, not immediately life-threatening; * Grade 4 Life-threatening; urgent intervention indicated; * Grade 5 Death due to AE.
| Participants | Zilucoplan+ Standard of Care | Zilucoplan Placebo Control | Zilucoplan Placebo + Standard of Care |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 65 | 47 | 4 |
| TEAE with a CTCAE grade ≥ 3 | 34 | 29 | 3 |
| Serious TEAE | 31 | 29 | 2 |
| TEAE leading to dose modification | 0 | 5 | 0 |
| TEAE leading to discontinuation of study drug | 7 | 5 | 1 |
Collected over From first dose of study drug to end of study (Day 60).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lanadelumab + SoC | 8/28 (28.6%) | 11/27 (40.7%) | 12/27 (44.4%) |
| Lanadelumab Placebo + SoC | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Apremilast + SoC | 37/194 (19.1%) | 51/189 (27%) | 63/189 (33.3%) |
| Apremilast Placebo + SoC | 35/184 (19%) | 55/182 (30.2%) | 50/182 (27.5%) |
| Zilucoplan + SoC | 20/100 (20%) | 31/95 (32.6%) | 46/95 (48.4%) |
| Zilucoplan Placebo + SoC | 3/8 (37.5%) | 2/7 (28.6%) | 4/7 (57.1%) |
| Event | Lanadelumab + SoC | Lanadelumab Placebo + SoC | Apremilast + SoC | Apremilast Placebo + SoC | Zilucoplan + SoC | Zilucoplan Placebo + SoC |
|---|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 3/27 | 1/1 | 6/189 | 6/182 | 2/95 | 0/7 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/27 | 0/1 | 11/189 | 6/182 | 5/95 | 1/7 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/27 | 0/1 | 14/189 | 10/182 | 8/95 | 1/7 |
| Septic shockInfections and infestations | 2/27 | 0/1 | 12/189 | 10/182 | 8/95 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 1/27 | 0/1 | 7/189 | 4/182 | 7/95 | 0/7 |
| Cardio-respiratory arrestCardiac disorders | 1/27 | 0/1 | 2/189 | 2/182 | 2/95 | 0/7 |
| Sinus bradycardiaCardiac disorders | 1/27 | 0/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| Pneumonia bacterialInfections and infestations | 1/27 | 0/1 | 1/189 | 1/182 | 2/95 | 0/7 |
| SepsisInfections and infestations | 1/27 | 0/1 | 3/189 | 3/182 | 1/95 | 0/7 |
| Staphylococcal infectionInfections and infestations | 1/27 | 0/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| Event | Lanadelumab + SoC | Lanadelumab Placebo + SoC | Apremilast + SoC | Apremilast Placebo + SoC | Zilucoplan + SoC | Zilucoplan Placebo + SoC |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/27 | 1/1 | 9/189 | 4/182 | 9/95 | 0/7 |
| LeukopeniaBlood and lymphatic system disorders | 0/27 | 1/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| BradycardiaCardiac disorders | 0/27 | 1/1 | 1/189 | 3/182 | 1/95 | 0/7 |
| Cardiac failure congestiveCardiac disorders | 0/27 | 1/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| TachycardiaCardiac disorders | 1/27 | 1/1 | 3/189 | 2/182 | 4/95 | 0/7 |
| Pneumonia klebsiellaInfections and infestations | 0/27 | 1/1 | 0/189 | 2/182 | 2/95 | 0/7 |
| Soft tissue injuryInjury, poisoning and procedural complications | 0/27 | 1/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| Oxygen saturation decreasedInvestigations | 0/27 | 1/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| AcidosisMetabolism and nutrition disorders | 0/27 | 1/1 | 0/189 | 0/182 | 0/95 | 0/7 |
| HypernatraemiaMetabolism and nutrition disorders | 2/27 | 1/1 | 4/189 | 3/182 | 3/95 | 1/7 |
Baseline characteristics are reported for the full analysis set, which includes all participants who were randomized to the sub-protocol candidate agent arm as well as all participants who were randomized to any placebo arm included in the control arm of the candidate agent. The Total number of participants (621) includes participants randomized to placebo and included in more than one placebo control group (106 participants); 515 unique participants were enrolled in the study.
| Age, Continuous(years) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol | 53.4 ± 15.34 | 59.6 ± 13.50 | — | — | — | — | 56.8 ± 14.57 |
| Apremilast Sub-protocol | — | — | 57.2 ± 13.84 | 55.7 ± 13.37 | — | — | 56.5 ± 13.61 |
| Zilucoplan Sub-protocol | — | — | — | — | 53.2 ± 14.13 | 58.4 ± 13.62 | 55.4 ± 14.11 |
| Age, Customized(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — ≥ 18 to ≤ 49 years | 13 | 8 | — | — | — | — | 21 |
| Lanadelumab Sub-protocol — ≥ 50 to ≤ 64 years | 7 | 15 | — | — | — | — | 22 |
| Lanadelumab Sub-protocol — ≥ 65 to ≤ 84 years | 8 | 10 | — | — | — | — | 18 |
| Lanadelumab Sub-protocol — ≥ 85 years | 0 | 1 | — | — | — | — | 1 |
| Apremilast Sub-protocol — ≥ 18 to ≤ 49 years | — | — | 51 | 56 | — | — | 107 |
| Apremilast Sub-protocol — ≥ 50 to ≤ 64 years | — | — | 76 | 81 | — | — | 157 |
| Apremilast Sub-protocol — ≥ 65 to ≤ 84 years | — | — | 64 | 52 | — | — | 116 |
| Apremilast Sub-protocol — ≥ 85 years | — | — | 3 | 1 | — | — | 4 |
| Zilucoplan Sub-protocol — ≥ 18 to ≤ 49 years | — | — | — | — | 45 | 19 | 64 |
| Zilucoplan Sub-protocol — ≥ 50 to ≤ 64 years | — | — | — | — | 36 | 29 | 65 |
| Zilucoplan Sub-protocol — ≥ 65 to ≤ 84 years | — | — | — | — | 16 | 26 | 42 |
| Zilucoplan Sub-protocol — ≥ 85 years | — | — | — | — | 3 | 1 | 4 |
| Sex: Female, Male(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — Female | 11 | 9 | 0 | 0 | 0 | 0 | 20 |
| Lanadelumab Sub-protocol — Male | 17 | 25 | 0 | 0 | 0 | 0 | 42 |
| Apremilast Sub-protocol — Female | 0 | 0 | 84 | 72 | 0 | 0 | 156 |
| Apremilast Sub-protocol — Male | 0 | 0 | 110 | 118 | 0 | 0 | 228 |
| Zilucoplan Sub-protocol — Female | 0 | 0 | 0 | 0 | 34 | 28 | 62 |
| Zilucoplan Sub-protocol — Male | 0 | 0 | 0 | 0 | 66 | 47 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — Hispanic or Latino | 18 | 19 | — | — | — | — | 37 |
| Lanadelumab Sub-protocol — Not Hispanic or Latino | 10 | 15 | — | — | — | — | 25 |
| Lanadelumab Sub-protocol — Unknown or Not Reported | 0 | 0 | — | — | — | — | 0 |
| Apremilast Sub-protocol — Hispanic or Latino | — | — | 75 | 72 | — | — | 147 |
| Apremilast Sub-protocol — Not Hispanic or Latino | — | — | 108 | 112 | — | — | 220 |
| Apremilast Sub-protocol — Unknown or Not Reported | — | — | 11 | 6 | — | — | 17 |
| Zilucoplan Sub-protocol — Hispanic or Latino | — | — | — | — | 65 | 32 | 97 |
| Zilucoplan Sub-protocol — Not Hispanic or Latino | — | — | — | — | 35 | 43 | 78 |
| Zilucoplan Sub-protocol — Unknown or Not Reported | — | — | — | — | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — American Indian or Alaska Native | 1 | 0 | — | — | 3 | 1 | 5 |
| Lanadelumab Sub-protocol — Asian | 0 | 0 | — | — | 3 | 5 | 8 |
| Lanadelumab Sub-protocol — Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | 0 | 0 | 0 |
| Lanadelumab Sub-protocol — Black or African American | 3 | 2 | — | — | 5 | 5 | 15 |
| Lanadelumab Sub-protocol — White | 20 | 28 | — | — | 75 | 58 | 181 |
| Lanadelumab Sub-protocol — More than one race | 2 | 1 | — | — | 8 | 2 | 13 |
| Lanadelumab Sub-protocol — Unknown or Not Reported | 2 | 3 | — | — | 6 | 4 | 15 |
| Apremilast Sub-protocol — American Indian or Alaska Native | — | — | 0 | 1 | — | — | 1 |
| Apremilast Sub-protocol — Asian | — | — | 11 | 7 | — | — | 18 |
| Apremilast Sub-protocol — Native Hawaiian or Other Pacific Islander | — | — | 0 | 1 | — | — | 1 |
| Apremilast Sub-protocol — Black or African American | — | — | 9 | 9 | — | — | 18 |
| Apremilast Sub-protocol — White | — | — | 151 | 151 | — | — | 302 |
| Apremilast Sub-protocol — More than one race | — | — | 4 | 7 | — | — | 11 |
| Apremilast Sub-protocol — Unknown or Not Reported | — | — | 19 | 14 | — | — | 33 |
| Zilucoplan Sub-protocol — American Indian or Alaska Native | — | — | — | — | 3 | 1 | 4 |
| Zilucoplan Sub-protocol — Asian | — | — | — | — | 3 | 5 | 8 |
| Zilucoplan Sub-protocol — Native Hawaiian or Other Pacific Islander | — | — | — | — | 0 | 0 | 0 |
| Zilucoplan Sub-protocol — Black or African American | — | — | — | — | 5 | 5 | 10 |
| Zilucoplan Sub-protocol — White | — | — | — | — | 75 | 58 | 133 |
| Zilucoplan Sub-protocol — More than one race | — | — | — | — | 8 | 2 | 10 |
| Zilucoplan Sub-protocol — Unknown or Not Reported | — | — | — | — | 6 | 4 | 10 |
| Region(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — North America | 9 | 9 | — | — | — | — | 18 |
| Lanadelumab Sub-protocol — Latin America | 18 | 20 | — | — | — | — | 38 |
| Lanadelumab Sub-protocol — Eastern Europe | 0 | 0 | — | — | — | — | 0 |
| Lanadelumab Sub-protocol — Rest of the World | 1 | 5 | — | — | — | — | 6 |
| Apremilast Sub-protocol — North America | — | — | 53 | 60 | — | — | 113 |
| Apremilast Sub-protocol — Latin America | — | — | 60 | 50 | — | — | 110 |
| Apremilast Sub-protocol — Eastern Europe | — | — | 51 | 53 | — | — | 104 |
| Apremilast Sub-protocol — Rest of the World | — | — | 30 | 27 | — | — | 57 |
| Zilucoplan Sub-protocol — North America | — | — | — | — | 26 | 10 | 36 |
| Zilucoplan Sub-protocol — Latin America | — | — | — | — | 65 | 33 | 98 |
| Zilucoplan Sub-protocol — Eastern Europe | — | — | — | — | 6 | 14 | 20 |
| Zilucoplan Sub-protocol — Rest of the World | — | — | — | — | 3 | 18 | 21 |
| Remdesivir Use at Baseline(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — Yes | 7 | 5 | — | — | — | — | 12 |
| Lanadelumab Sub-protocol — No | 21 | 29 | — | — | — | — | 50 |
| Apremilast Sub-protocol — Yes | — | — | 45 | 44 | — | — | 89 |
| Apremilast Sub-protocol — No | — | — | 149 | 146 | — | — | 295 |
| Zilucoplan Sub-protocol — Yes | — | — | — | — | 22 | 9 | 31 |
| Zilucoplan Sub-protocol — No | — | — | — | — | 78 | 66 | 144 |
| Clinical Severity Score of 2(Participants) | Lanadelumab + Standard of Care | Lanadelumab Placebo Control | Apremilast + Standard of Care | Apremilast Placebo Control | Zilucoplan + Standard of Care | Zilucoplan Placebo +Control | Total |
|---|---|---|---|---|---|---|---|
| Lanadelumab Sub-protocol — Yes (Grade 2) | 3 | 4 | — | — | — | — | 7 |
| Lanadelumab Sub-protocol — No (Grade 3-5) | 25 | 30 | — | — | — | — | 55 |
| Apremilast Sub-protocol — Yes (Grade 2) | — | — | 11 | 9 | — | — | 20 |
| Apremilast Sub-protocol — No (Grade 3-5) | — | — | 183 | 181 | — | — | 364 |
| Zilucoplan Sub-protocol — Yes (Grade 2) | — | — | — | — | 8 | 6 | 14 |
| Zilucoplan Sub-protocol — No (Grade 3-5) | — | — | — | — | 92 | 69 | 161 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Nov 2020 to primary completion in Aug 2021, 8 months.
Results were first posted in Jun 2022, 10 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apremilast · Lanadelumab · Zilucoplan